The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2020

Filed:

Feb. 05, 2019
Applicant:

Robert P. Doyle, Manlius, NY (US);

Inventor:

Robert P. Doyle, Manlius, NY (US);

Assignee:

Syracuse University, Syracuse, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/55 (2017.01); A61K 38/17 (2006.01); A61K 31/714 (2006.01); A61K 38/26 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/551 (2017.08); A61K 31/714 (2013.01); A61K 38/1703 (2013.01); A61K 38/26 (2013.01); A61K 49/0032 (2013.01); A61K 49/0052 (2013.01);
Abstract

A method for the avoidance of side effects associated with glucagon-like peptide-1 receptor (GLP-1R) agonists through vitamin Bconjugation prior to administration. Vitamin Bmay be bound to a GLP-1R agonist, such as exendin-4 (Ex4), to provide enhanced proteolytic stability while retaining GLP-1R agonism. The conjugate (B-Ex4) also improves glucose tolerance without producing anorexia and malaise. A GLP-1R agonist that is resistant to DPP-IV degradation and does not penetrate readily into the CNS, but retains the enhanced pharmacokinetic and pharmacodynamic profile on pancreatic β-cells provide a pharmacological tool for glycemic control in type 2 diabetes mellitus (T2DM) patients without eliciting unwanted hypophagia and nausea.


Find Patent Forward Citations

Loading…